Multiple myeloma (MM) is a malignant plasma cell disease that currently cannot be cured. Several new drugs have continuously been introduced in the recent years. New drugs targeting B-cell maturation antigen (BCMA) have greatly improved the efficacy and prognosis of MM compared with traditional treatments. This article reports the case of an IgD type relapsed and refractory MM patient with poor efficacy of BCMA×CD3 bispecific antibody. The patient achieved deep remission after receiving BCMA-targeted CAR-T cell therapy after initial seven lines of treatment. Literature review was also conducted to improve the clinical physicians' understanding of BCMA target therapy for relapsed and refractory MM patients.
多发性骨髓瘤（MM）是一种恶性浆细胞疾病，目前仍无法治愈。近年来，新药不断问世，与传统治疗相比，以B细胞成熟抗原（BCMA）为靶点的新药极大地改善了MM的疗效及预后。本文报道1例BCMA×CD3双特异性抗体治疗失败的IgD型复发难治MM患者，经过七线治疗，再次接受基于BCMA靶点的CAR-T细胞治疗后获得深度缓解，并进行相关文献复习，以期提高临床医师对复发难治MM患者BCMA靶点再治疗的认识。.